-
ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases
ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, today announces the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.” The patent application which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach,…
-
TR1 from Lanstead Capital – Major interest in shares
Standard form for notification of major holdings To view click here
-
INTERIM RESULTS for the six months ended 30 June 2025
ImmuPharma PLC (LSE:IMM), (“ImmuPharma”, the Group or the “Company”), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2025 (the “Period”). Key Highlights (including post Period review) Financials For the period ended 30 June 2025, the Group reported a loss of £1.8…
-
2025 Result of Annual General Meeting
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 – 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details…
-
TR1 from Lanstead – Major interest in shares
TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
-
Notice of AGM and Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…
-
FINAL RESULTS for the twelve months ended 31 December 2024
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2024 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £2.5m (2023: £2.9m) Research and development expenses of £1.2m (2023: £2.0m) Administrative…
-
Extension of Warrants in Incanthera to 30 September 2025
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed – by means of a Deed of Variation – with Incanthera plc (“Incanthera”), that warrants issued to the Company on 26 February 2020 (“Warrants”), in conjunction with Incanthera’s IPO onto the Aquis Exchange (“AQSE”), are…
-
Zaks Traders Cafe
Zak Mir talks to Tim McCarthy, CEO ImmuPharma, in the wake of a series of announcements this year which have transformed the outlook for the AIM listed (LSE:IMM) evolving speciality pharma company. 17 March 2025 Tim McCarthy, CEO of ImmuPharma talks to Zak MIr at ‘Traders Cafe’ focusing on the UK biotech arena as a…
-
Sunday Roast
Sunday Roast-Tim, CEO #IMM 16 March 2025 ImmuPharma’s CEO, Tim McCarthy talks again to Sunday Roast investment podcast, to give detail on the recent announcement on the mechanism of action of IMMs autoimmune P140 technology and how important this is in current and future business development discussions – March 2025
